Abstract
Antipsychotic medicines are the cornerstone pharmacotherapy for patients with psychotic disorders. Early and continuous management of psychoses improves the quality of life, decreases hospitalization and reduces medical costs. However, many psychotic patients are not fully compliant with treatment, and thus they more often experience a relapsing course with a suboptimal clinical outcome. Long-term parenteral antipsychotic agents may improve compliance by offering clear evidence of medication non-compliance and documented drug administration monitoring. Using injection therapy might be especially beneficial to poorly compliant individuals with their first-psychotic episode and those with severe psychopathology or comorbid substance abuse. The availability of five different antipsychotic drug depot medications offers diverse treatment options which can be individualized for each case.
Keywords: Injectable antipsychotic medications, depot neuroleptic agents, haloperidol decanoate, fluphenazine decanoate, long-acting risperidone, paliperidone palmitate, long-acting olanzapine, psychotherapy, CATIE, neuroleptic
Current Drug Targets
Title: Long-Acting Antipsychotic Medications
Volume: 13 Issue: 4
Author(s): Raman Baweja, Karim Sedky and Steven Lippmann
Affiliation:
Keywords: Injectable antipsychotic medications, depot neuroleptic agents, haloperidol decanoate, fluphenazine decanoate, long-acting risperidone, paliperidone palmitate, long-acting olanzapine, psychotherapy, CATIE, neuroleptic
Abstract: Antipsychotic medicines are the cornerstone pharmacotherapy for patients with psychotic disorders. Early and continuous management of psychoses improves the quality of life, decreases hospitalization and reduces medical costs. However, many psychotic patients are not fully compliant with treatment, and thus they more often experience a relapsing course with a suboptimal clinical outcome. Long-term parenteral antipsychotic agents may improve compliance by offering clear evidence of medication non-compliance and documented drug administration monitoring. Using injection therapy might be especially beneficial to poorly compliant individuals with their first-psychotic episode and those with severe psychopathology or comorbid substance abuse. The availability of five different antipsychotic drug depot medications offers diverse treatment options which can be individualized for each case.
Export Options
About this article
Cite this article as:
Baweja Raman, Sedky Karim and Lippmann Steven, Long-Acting Antipsychotic Medications, Current Drug Targets 2012; 13 (4) . https://dx.doi.org/10.2174/138945012799499785
DOI https://dx.doi.org/10.2174/138945012799499785 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Effectiveness of Long-Term Macrolide Therapy in Cryptogenic Organising Pneumonia
Current Respiratory Medicine Reviews Cytokine Gene Variants as Predictors of Type 2 Diabetes Mellitus
Current Diabetes Reviews The Neuroprotective Effect of Ginkgo biloba Leaf Extract and its Possible Mechanism
Central Nervous System Agents in Medicinal Chemistry Prostaglandin EP Receptor Subtypes Involved in Regulating HCO3- Secretion from Gastroduodenal Mucosa
Current Pharmaceutical Design Ibubrofen in the Treatment of Patent Ductus Arteriosus in Preterm Infants: What We Know, What We Still Do Not Know
Current Pharmaceutical Design Editorial Statins: [Hot Topic: Statins: Effects Beyond Cholesterol Lowering (Guest Editor: Garry X. Shen)]
Current Drug Targets - Cardiovascular & Hematological Disorders HPLC as a Tool in Medicinal Chemistry for the Monitoring of Tricyclic Antidepressants in Biofluids
Mini-Reviews in Medicinal Chemistry Pharmacological, Immunological, and Gene Targeting of the Renin-Angiotensin System for Treatment of Cardiovascular Disease
Current Pharmaceutical Design Protective Effects of Astragalus Membranaceus and Ligustrazine on Rat Brain Microvascular Endothelial Cell Injury after Oxygen-Glucose Deprivation/ Reoxygenation by Suppressing the PKCδ/MARCKS Pathway
Combinatorial Chemistry & High Throughput Screening Targeting Metabolic Enzymes in Cancer – Clinical Trials Update
Current Enzyme Inhibition The Coronin Family and Human Disease
Current Protein & Peptide Science Molecular Mechanisms Underlying Psychological Stress and Cancer
Current Pharmaceutical Design Coronary Artery Disease and Endothelial Dysfunction: Novel Diagnostic and Therapeutic Approaches
Current Medicinal Chemistry HMG-Co A Reductase Inhibitors in the Treatment of Cardiovascular Diseases: Stabilization of Coronary Artery Plaque
Current Drug Targets Heart Failure in the Middle East
Current Cardiology Reviews Role of Oxidative Stress in Development of Cardiovascular Complications in Diabetes Mellitus
Current Vascular Pharmacology Mutations and Common Polymorphisms in ADAMTS13 and vWF Genes Responsible for Increasing Risk of Thrombosis
Cardiovascular & Hematological Disorders-Drug Targets Cardioprotective Effects of the Polyphenol Hydroxytyrosol from Olive Oil
Current Drug Targets Homocysteine, Intracellular Signaling and Thrombotic Disorders
Current Medicinal Chemistry Pharmacological and Biological Activities of Xanthones
Anti-Infective Agents in Medicinal Chemistry